Source: ChildrensHealthDefense.org
The U.S. Food and Drug Administration approved Recombivax HB, the hepatitis B vaccine for newborns, based on clinical trials performed on only 147 infants and children who were monitored for just five days.
Story at a glance:
- The safety data on Recombivax HB, the hepatitis B vaccine for newborns, are sadly lacking, as the U.S. Food and Drug Administration (FDA) approved the shot based on clinical trials performed on only 147 infants and children and followed for only five days.
- There are four hepatitis B vaccines, two of which are approved for infants; the second approved for infants is Engerix-B, and clinical safety data show infants and children were followed for only four days in these trials.
- Most infants are not at high risk for hepatitis B. It makes better financial and health sense to test mothers before birth and vaccinate only those infants born to mothers with an active or chronic hepatitis B infection, putting off vaccination in other infants until they are older.
- The current childhood vaccination schedule includes 19 potential doses of vaccines and one mRNA experimental injection by the time an infant is 6 months old. Many of these contain aluminum, which raises a child’s risk of persistent asthma in childhood.
As the pandemic years have made abundantly obvious, the results of politically and financially driven public health policies can be devastating.
And, as more and more vaccines get added to both child and adult schedules, it’s becoming clear there needs to be an open and rational discussion about how vaccines fit into public health policy and what they offer in protection against infectious diseases.
One thing that is certain is we all want our children to be healthy and safe from unnecessary harm.
However, as lead attorney for Informed Consent Action Network (ICAN), Aaron Siri explains, just one example of the negligence in regulations is the sadly lacking safety data on the hepatitis B vaccine for newborns….